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Aspergillus spp. are among the most common causes of opportunistic invasive fungal infections in tertiary care hospitals. Little is
known about the prevalence and in vitro susceptibility of Aspergillus species in Latin America, because there are fewmedical
centers able to perform accurate identification at the species level. The purpose of this study was to analyze the distribution of
cryptic and rare Aspergillus species among clinical samples from 133 patients with suspected aspergillosis admitted in 12 medical
centers in Brazil and to analyze the in vitro activity of different antifungal drugs. The identification of Aspergillus species was
performed based on a polyphasic approach, as well as sequencing analysis of the internal transcribed spacer (ITS) region, cal-
modulin, and -tubulin genes and phylogenetic analysis when necessary. The in vitro susceptibility tests with voriconazole, po-
saconazole, and itraconazole were performed according to the CLSI M38-A2 document (2008). We demonstrated a high preva-
lence of cryptic species causing human infection. Only three isolates, representing the species Aspergillus thermomutatus, A.
ochraceus, and A. calidoustus, showed less in vitro susceptibility to at least one of the triazoles tested. Accurate identifications of
Aspergillus at the species level and with in vitro susceptibility tests are important because some species may present unique resis-
tance patterns against specific antifungal drugs.
Aspergillus is a ubiquitous fungus that is responsible for a widespectrum of infections. One of the most important clinical
manifestations ofAspergillus is invasive aspergillosis (IA), which is
associated with high morbidity and mortality rates (1, 2). The
genus Aspergillus is divided into eight subgenera that in turn are
subdivided into several sections that include a large variety of
closely related species (3, 4). The most clinically relevant sections
are Fumigati, Flavi, Terrei,Usti,Nigri, andNidulantes (5). Molec-
ular studies have revealed numerous cryptic species within the
different sections of the genus Aspergillus (6).
Historically,Aspergillus has been identified in the laboratory by
conventional methods such as colony morphology and micro-
scopic characteristics.However, there is a consensus thatmorpho-
logical characteristics may not be reliable for distinguishing be-
tween Aspergillus species (7). Despite its clinical relevance and
several comprehensive studies dealing with the taxonomy of
Aspergillus in the last few years, the taxonomy of Aspergillus re-
mains somewhat ill defined. For consistent species identification,
analyses of morphological, physiological, and molecular charac-
teristics are required (7, 8). As this process is not suitable for rou-
tine testing by clinical microbiological laboratories, identification
of Aspergillus clinical isolates at the species level has been scarcely
reported (9). The accurate identification of species is critical given
that different species may present peculiarities in terms of reser-
voir, virulence factors, natural history of infection, and in vitro
susceptibility to antifungal drugs (10, 11).
The aim of this study was to analyze the distribution of Asper-
gillus species among clinical samples isolated from 133 patients
with suspected aspergillosis admitted to 12medical centers in Bra-
zil and to analyze the in vitro antifungal susceptibility profiles of
rare and cryptic species within the genus.
MATERIALS AND METHODS
Fungal isolates.We selected 133 isolates previously identified asAspergil-
lus spp. obtained from 133 different patients admitted to 12 medical cen-
ters in Brazil between 2006 and 2013. All isolates were interpreted as
pathogens by the clinicians following the criteria suggested by the Euro-
peanOrganization forResearch andTreatment ofCancer/Invasive Fungal
Infections Cooperative Group, National Institute of Allergy and Infec-
tiousDiseasesMycoses StudyGroup (EORTC/MSG) before being sent for
further identification in our reference lab. The isolates were grown on
slanted potato dextrose agar (PDA) (Difco Laboratories, Detroit, MI,
USA) for 7 days at 25°C and were covered with mineral oil for long-term
room temperature storage until analysis.
Morphological examination and thermotolerance.The isolates were
grownonPDA,malt extract agar (MEA) (Difco Laboratories, Detroit,MI,
USA), and Czapek agar (CZK) (Difco Laboratories, Detroit, MI, USA).
The fungi were inoculated at three points on duplicate plates of each
medium and incubated at 15, 25, 37, 42, and 50°C for 14 days in the dark
(12). Micromorphology observations were performed on microscopic
mounts prepared in lactic acid fromMEA colonies. The thermotolerance
test involved assessment of the presence or absence of fungal growth at
different temperatures (8).
Molecular identification: DNA extraction, amplification, and se-
quencing of ITS, calmodulin, and -tubulin genes. The isolates were
grown on yeast extract sucrose agar (YES) (10 g yeast extract, 75 g sucrose,
10 g agar, and 500 ml distilled water). Then, DNA was extracted with the
PrepMan Ultra sample preparation reagent (Applied Biosystems, Foster
City, CA, USA) according to the manufacturer’s instructions. The DNA
concentration and purity (relative to proteins and salts) were determined
by optical density at 260 nm (OD260) and ratios of OD260/280 and
OD260/230, respectively. Fragments of the calmodulin (CAL) and -tubu-
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lin (BT2) genes and the internal transcribed spacer (ITS) region of rDNA
were amplified with the primer pairs cl1/cl2a, bt2a/bt2b (13), and ITS1/
ITS4, respectively. The reactions were performed with PCR master mix
(Promega, Madison, WI, USA) according to the manufacturer’s instruc-
tions. After amplification, the fragments were sequenced following the
protocol provided with the BigDye reagent kit (Applied Biosystems, Fos-
ter City, CA, USA) in an ABI 3130 (Applied Biosystems, Foster City, CA,
USA) automatic sequencer. PCR products were sequenced with the same
primers used for amplification. Contig assembly and editing were per-
formed with Sequencher DNA sequence assembly software 4.1.4 (Gene
Codes Corporation, Ann Arbor, MI, USA). Successful assembly of the
contigs required a minimum match percentage of 85 and a minimum
overlap of 20.
BLAST analysis. Complete CAL, BT2, and ITS consensus sequences
were used to conduct BLAST search analysis (BLASTn) for species iden-
tification from the NCBI genomic database (http://blast.ncbi.nlm.nih.gov/).
For all regions analyzed by BLAST search, the sequences that presented
with high identity (99%), queries and E values of e105 were considered
for the final species identification using the sequencing method.
The identification of Aspergillus species was performed based onmac-
romorphology, micromorphology, and thermotolerance of the colonies,
as well as on sequence comparisons of the ITS region and the calmodulin
and-tubulin geneswith published sequences in genomic databases. Phy-
logenetic analyses using Bayesian inference and maximum parsimony
methodologies were performed to characterize isolates with inconsistent
identification by morphological and genotypic analysis.
Phylogenetic analysis. Most-parsimonious analysis was carried out
for all data sets using PAUP* version 4.0b10 (14). One hundred heuristic
searches were conducted using random sequence addition and tree bisec-
tion-reconnection branch-swapping algorithms, collapsing zero-length
branches, and saving allminimal-length trees (MulTrees) on different sets
of data. Gaps were treated as missing data. Support for internal branches
was assessed by a heuristic parsimony search of 1,000 bootstrapped sets of
data. Other measures were also taken, including tree length, consistency
index (CI), homoplasy index (HI), and retention index (RI). The com-
bined data set was tested for incongruencewith the partition homogeneity
test as implemented in PAUP*. The alignments used in the phylogenetic
analysis were deposited in TreeBASE (www.treebase.org).
Bayesian posterior probabilities were calculated using MrBayes 3.12
TABLE 1 GenBank accession numbers of the nucleotide sequences
representatives of each identified species and reference strains included
in this study
Aspergillus species Straina
GenBank accession no. for:
-Tubulin Calmodulin
A. flavus CBS 100927NT AY819992.1 EF202063.1
A. flavus LEMI803 KJ767726 KJ766990
A. flavus LEMI925 KJ767727 KJ766989
A. flavus LEMI953 KJ767728 KJ766988
A. flavus LEMI896 KJ767729 KJ766987
A. arachidicola CBS 117610T EF203158 EF202049.1
A. arachidicola LEMI760 KJ767720 KJ767736
A. minisclerotigenes CBS 117620 EF203150.1 EF202073.1
A. parasiticus CBS 100926NT EF203155.1 EF202043.1
A. sergii MUM 10.219T HM803082 HM803029
A. transmontanensis MUM 10.214T HM803101 HM803020
A. transmontanensis LEMI800 KJ766997 KJ767732
A. nomius NRRL 13137T EF661494.1 EF661531.1
A. nomius LEMI878 KJ767725 KJ767731
A. oryzae var. effusus NRRL 506T JN185446.1 JN185447.1
A. oryzae NRRL 447T EF661483.1 EF661506.1
A. sojae CBS 100928T EF203168.1 EF202041.1
A. tamarii NRRL 20818T EF661474.1 EF661526.1
A. tamarii LEMI436 KJ767721 KJ767722
A. tamarii LEMI999 KJ767733 KJ767735
A. caelatus NRRL 25528T EF661470.1 AF255036.1
A. tennesseensis NRRL 13150T JN853976.1 JN854017.1
A. tennesseensis LEMI875 KJ766999 KJ766995
A. tennesseensis LEMI917 KJ766998 KJ766994
A. tennesseensis LEMI870 KJ767000 KJ766996
A. puulaauensis NRRL 35641T JN853979.1 JN854034.1
A. puulaauensis NRRL 58602 JN853999.1 JN854048.1
A. cvjetkovicii NRRL 227T EF652264.1 EF652352.1
A. cvjetkovicii NRRL 58593 JN853998.1 JN854044.1
A. cvjetkovicii NRRL 4642 EF652291.1 EF652379.1
A. creber NRRL 58592T JN853980.1 JN854043.1
A. subversicolor NRRL 58999T JN853970.1 JN854010.1
A. asperescens NRRL 4770T EF652299.1 EF652387.1
A. multicolor NRRL 4775T EF652301.1 EF652389.1
A. awamori CCF 4068T HE661602.1 FR751414.1
A. awamori LEMI1010/LEMI993 KJ777804 KJ777809
A. foetidus CBS564.65 GU296697.1 FN594547.1
A. foetidus LEMI891 KJ777808 KJ777811
A. tubingensis CBS 134.48T FJ629305.1 FN594558.1
A. creber NRRL 58673T JN853993.1 JN854056.1
A. creber NRRL 58670 JN853991.1 JN854053.1
A. creber NRRL 58672 JN853992.1 JN854055.1
A. creber LEMI984 KJ767001 KJ766991
A. jensenii NRRL 58600T JN854007.1 JN854046.1
A. jensenii NRRL 225 JN854000.1 JN854020.1
A. jensenii NRRL 235 JN854001.1 JN854027.1
A. jensenii NRRL 240 JN854002.1 JN854030.1
A. venenatus NRRL 13147T JN854003.1 JN854014.1
A. venenatus NRRL 13148 JN854004.1 JN854015.1
A. venenatus NRRL 13149 JN854005.1 JN854016.1
A. sydowii NRRL 250T EF652274.1 EF652362.1
A. sydowii NRRL 254 EF652275.1 EF652363.1
A. sydowii NRRL 4768 EF652297.1 EF652385.1
A. sydowii NRRL 5585 JN853936.1 JN854039.1
A. austroafricanus NRRL 233T JN853963.1 JN854025.1
A. protuberus NRRL 3505T EF652284.1 EF652372.1
A. protuberus NRRL 58942 JN853956.1 JN854061.1
A. protuberus NRRL 58748 JN853967.1 JN854060.1
A. amoenus NRRL35600 JN853952.1 JN854033.1
TABLE 1 (Continued)
Aspergillus species Straina
GenBank accession no. for:
-Tubulin Calmodulin
A. amoenus NRRL 4838T EF652304.1 EF652392.1
A. amoenus NRRL 226 JN853939.1 JN854021.1
A. amoenus NRRL 236 JN853940.1 JN854028.1
A. tabacinus NRRL 4791T EF652302.1 EF652390.1
A. tabacinus NRRL A-23173 JN853960.1 JN854065.1
A. tabacinus NRRL 5031 JN853947.1 JN854036.1
A. tabacinus LEMI968 KJ767002 KJ766992
A. versicolor NRRL 13145 JN853950.1 JN854012.1
A. versicolor NRRL 13144 JN853949.1 JN854011.1
A. versicolor NRRL 13146 JN853951.1 JN854013.1
A. fructus NRRL 241 JN853943.1 JN854031.1
A. niger CBS 554.65T FJ629288.1 FN594540.1
A. niger LEMI975 KJ777807 KJ777813
A. thermomutatus LEMI918 KJ767003 KJ766993
A. ochraceus LEMI966 KJ767724 KJ767730
A. clavatus LEMI40 KJ767723 KJ767734
A. terreus LEMI941 KJ777806 KJ777812
A. calidoustus LEMI749 KJ777803 KJ790258
A. fumigatus LEMI864 KJ777805 KJ777810
a T, type strain; NT, neotype strain.
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(15). A neighbor-joining (NJ) tree was analyzed in the ModelTest pro-
gram to estimate the bestmodel of nucleotide substitution for application
on the phylogeny inference. A general time-reversible (GTR) model was
used with a proportion of invariant sites and a gamma-shaped distribu-
tion of rates across the sites.Markov chainMonteCarlo (MCMC) analysis
was conducted for up to 1  106 generations until the chain converged.
Concordance analysis was based on the exclusionary principle of Baum
and Shaw (16) and the genealogical concordance phylogenetic species
recognition concepts of Taylor et al. (17). Clades were recognized as in-
dependent evolutionary lineages if a clade was strongly supported by both
parsimony and Bayesian analysis in at least one locus and the result was
not contradicted by another strongly supported locus. Strong support was
assessed at 70% bootstrap and 0.95 Bayesian posterior probability
(11, 18, 19).
Nucleotide sequence accession numbers. The nucleotide sequence
representatives of each identified species in this study were deposited in
the GenBank database under the accession numbers given in Table 1.
Antifungal susceptibility tests. Antifungal susceptibility testing was
performed as outlined in the Clinical and Laboratory Standards Institute
(CLSI) M38-A2 protocol (20). The isolates were cultured on PDA and
incubated at 25°C for 7 days to prepare the fungal inocula. Briefly, 100-l
culture preparations in RPMI 1640 (Vitrocell, Campinas, São Paulo, Bra-
zil) were inoculated into the flat-bottomwells of 96-well microtiter plates
containing 100l of the drug dilutions. The final inoculum concentration
ranged from0.4 104 to 5 104CFU/ml. The drugs testedwere provided
by the manufacturers as pure powders and included itraconazole (ITC)
(Sigma, Janssen Pharmaceutica, Beerse, Antwerp, Belgium), voriconazole
(VRC) (Sigma, Pfizer, Inc., New York, NY, USA), and posaconazole
(PSC) (Schering-Plough, Inc., Kenilworth, IL, USA). The MIC values
were determined visually as the lowest concentrations that resulted in
complete growth inhibition. Tests were performed in duplicate, andwhen
the results did not concur, the test was repeated and themode of theMICs
was considered (11, 21).
RESULTS
Screening of Aspergillus sections. Based on morphological char-
acterization, 133 isolates were classified into 9 different sections:
Fumigati (n 72), Flavi (n 37),Nigri (n 13),Nidulantes (n
5), Terrei (n  2), Circumdati (n  1), Usti (n  1), Flavipedes
(n 1), and Clavati (n 1).
BLAST analysis of the ITS region sequences confirmed our
morphological findings and the phenotypic identification of those
sections.
Identification of species by polyphasic approach. BLAST of
calmodulin and-tubulin gene sequences together withmorpho-
logical and ITS characterization provided consistent identifica-
tion at the species level of 82 out of the 133 isolates tested. All of the
species from Fumigati, Circumdati, Usti, Terrei, Flavipedes, and
Clavati sections were identified using the polyphasic approach
(morphology, thermotolerance, and sequencing) without requir-
ing further phylogeny analyses.However, those tools did not iden-
tify 35 isolates of the Flavi section, 11 isolates from the Nigri sec-
tion, and 5 isolates from the Nidulantes section.
Thermotolerance testing was useful in the discrimination of
closely related species within the sectionsCircumdati (A. ochraceus
versus A. westerdijkiae), Usti (A. ustus versus A. calidoustus), and
Fumigati (A. fumigatus versus A. thermomutatus). Another inter-
esting finding was that only the A. fumigatus strains grew at 50°C.
The 51 isolates from the Flavi, Nigri, and Nidulantes sections that
were not identified at the species level using the strategies outlined
above underwent further phylogenetic analysis.
Phylogenetic analysis of the Flavi,Nigri, andNidulantes sec-
tions. The results of the partition homogeneity test on sections
Flavi,Nigri, andNidulantes showed that the sequence data sets for
the two selected loci (BT2 and CAL) were congruent and could
therefore be combined (P  0.1667, 0.1667, and 0.333, respec-
tively).
The combined gene fragments generated by BT2 and CAL se-
quencing from Flavi, Nigri, and Nidulantes sections were 990 bp,
1,047 bp, and 1,372 bp, respectively. Unambiguous sequences of
type and neotype strains corresponding to potential species to be
identified were inserted into the analysis (Table 1). The analysis also
included previously identified strains to function as outgroups.
Section Flavi.Amost-parsimonious tree of 235 steps in length
with a CI of 0.8340, HI of 0.1660, and RI of 0.9286 was produced
from a heuristic search using the combined data set of 990 char-
acters from two loci (Fig. 1), including 811 constant, 130 variable
parsimony-informative, and 49 variable and parsimony-uninfor-
mative characters. After the analysis, we noted the presence of 3
main groups with well-supported clades. (i) Group I, denomi-
nated A. parasiticus complex, with 85% of bootstrap (bs) and
Bayesian posterior probability (bpp) of 0.95 included 5 clinical
isolates, type and neotype strains of A. parasiticus, A. sojae, A.
transmontanensis, and A. arachidicola. One isolate (LEMI760) al-
located as A. arachidicola and another isolate (LEMI800) as A.
transmontanensis. Three isolates grouped apart from the reference
strains and were named Aspergillus sp. 1. (ii) Group II, named A.
flavus complex (100% bs and 1 bpp), contained 29 clinical isolates
and type and neotype strains of A. flavus, A. oryzae, and A. oryzae
var. effusus. The type strain sequences of A. minisclerotigenes and
A. sergii were phylogenetically close to the A. flavus complex but
were not grouped with any isolate. (iii) Group III (100% bs and 1
bpp) was subdivided into two subgroups. One subgroup included
two clinical isolates and a type strain of A. tamarii. The other
group included one clinical isolate and a type strain of A. nomius.
Notably,A. tamarii andA. nomiuswere previously identified using
morphological features and BLAST analysis.
SectionNigri.Amost-parsimonious tree of 117 steps in length
with a CI of 0.9316, HI of 0.0684, and RI of 0.9535 was produced
from a heuristic search using the combined data set of 1,047 char-
acters from two loci (Fig. 2), including: 943 constant, 65 variable
parsimony informative, and 39 variable and parsimony uninfor-
mative. After analysis, we noted the presence of 2 main groups
with well-supported clades. Group I (100% bs and 1 bpp) was
subdivided into other 2 subgroups, (i) the subgroup A. niger
(100% bs and 0.96 bpp), which contained 4 clinical isolates and
one type strain of A. niger, and (ii) the subgroup A. awamori
(100% bs and 0.95 bpp), which contained 7 clinical isolates and
one type strain of A. awamori. This subgroup was also subdivided
into 2 groups. One of them contained 4 clinical isolates and no
reference sequences (Aspergillus sp. 2), and the other contained 3
clinical isolates and one type strain of A. awamori. The isolate
LEMI926 was related to subgroup A. awamori but was not identi-
fied. We referred to this isolate as Aspergillus sp. 3. Group 2, also
with 100% bs and 1 bpp, included one clinical isolate, one type
strain of A. foetidus, and one separate branch with one type strain
sequence of A. tubingensis.
Section Nidulantes. A most-parsimonious tree of 535 steps
long with a CI of 0.8224, HI of 0.1776, and RI of 0.9251 was
produced from a heuristic search using the combined data set of
1,372 characters from two loci (Fig. 3), including 1,009 constant,
188 variable parsimony informative, and 175 variable and parsi-
mony uninformative. After the analysis, we noted the presence of
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2 main groups. Group I was a well-supported clade (100% bs and
1 bpp) subdivided into two other subgroups, versicolor and sy-
dowii. The subgroup versicolor (100%bs and 1 bpp) contained one
clinical isolate and one type strain from each of the following
species: A. tabacinus, A. fructus, A. versicolor, A. austroafricanus,
andA. protuberus. The LEMI968 isolate grouped with theA. taba-
cinus type strain. The subgroup sydowii (100% bs and 1 bpp) con-
tained 4 clinical isolates and 1 type strain of A. sydowii, A. venena-
tus, A. cvjetkovicii, A. creber, A. puulaauensis, A. tennesseensis, and
A. jensenii. The clinical isolate LEMI984 clustered with the refer-
ence sequences of A. creber with 100% bs and 1 bpp. The other 3
clinical isolates (LEMI875, LEMI917, and LEMI870) grouped
with reference sequences of A. tennesseensis. Group II, with 100%
bp and 0.97 bpp, consisted of A. asperescens and A. multicolor
sequences. The reference sequences of A. subversicolor were used
as outgroups.
Final species identification and susceptibility profiles to tria-
zoles. According to data generated by conventional molecular
tools and phylogenetic analysis, A. fumigatus was found to be the
most prevalent species, with 71 (53%) isolates, followed by A.
FIG 1 Aspergillus section Flavi. Most-parsimonious tree obtained from a heuristic search based on parsimony analysis of the data produced from the BT2 and
CAL genes combined. The numbers at the nodes of the branches are bootstrap values/Bayesian posterior probability. Clinical isolates are designated in bold. T,
type strain; NT, neotype strain. Bar, 0.1 nucleotide changes between taxa.
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flavuswith 29 (22%) isolates andA. nigerwith only 4 (3%) isolates.
The following less frequent or rare species were also found: A.
clavatus (n 1),A. flavipes (n 1), andA. terreus (n 2). Among
the cryptic species found in Brazilian clinical samples, the most
frequent was Aspergillus sp. 2 undescribed species (4 isolates, sec-
tion Flavi), followed by A. awamori (sectionNigri), Aspergillus sp.
1 undescribed species (section Flavi), andA. tennesseensis (section
Nidulantes), with 3 isolates each. Other species found were related
to Flavi (2 A. tamarii strains, 1 A. arachidicola strain, 1 A. trans-
montanensis strain, and 1 A. nomius strain), Fumigati (1 A. ther-
momutatus strain), Circumdati (1 A. ochraceus strain), Nidulantes
(1 A. tabacinus strain and 1 A. creber strain), Nigri (1 A. foetidus
strain and 1 Aspergillus sp. 3 strain), and Usti (1 A. calidoustus
strain).We observed that 8 isolates fromour study (32%of cryptic
species) were not identified by any of our 3 appliedmethodologies
and possibly represent new Aspergillus species (Table 2).
Of note, only three cryptic species isolates (A. calidoustus, A.
thermomutatus, and A. ochraceus) presented high MIC values
against at least one of the triazoles tested (Table 2). The A. calid-
oustus isolate presented highMIC values against all triazoles tested
(MICs of 4g/ml against voriconazole andposaconazole and32
g/ml against itraconazole). The isolate of A. thermomutatus
showed high MIC values against itraconazole and voriconazole, 2
and 16 g/ml, respectively. The A. ochraceus isolate presented a
high MIC value (4 g/ml) only against itraconazole. The other
isolates of Aspergillus cryptic species showed MIC values ranging
from 0.03 and 2 g/ml for all triazoles studied.
DISCUSSION
Advances in genomic and molecular tools have provided im-
proved conditions for the classification of all microorganisms, in-
cluding fungal species. Following the application of new molecu-
lar tools in taxonomic studies of the Aspergillus genus, a large
number of new species have been described in the past fewdecades
(6). This new information has driven the attention of the medical
community to an increasing number of invasive fungal infections
caused by rare and cryptic species of Aspergillus that in the recent
past had been misidentified and most likely underestimated (6).
A variety of factors have all contributed to an increase in the
number of people at risk of developing fungal infections, includ-
ing by agents that had never been described as human pathogens.
These factors include an aging population, large numbers of pa-
tients with degenerative and neoplastic diseases, patients who
have had solid organ and hematopoietic stem cell transplanta-
tions, and patients under immunosuppressive therapy (22, 23).
The most common species implicated in IA is Aspergillus fu-
migatus. Other Aspergillus species, including A. flavus, A. niger, A.
terreus, and A. ustus, have also been reported as pathogens. Asper-
gillus flavushas been described as the secondmost commonAsper-
gillus species in several medical centers from Europe and the
United States, whereasA. terreus is particularly frequent in Austria
(6th Trends in Medical Mycology Workshop, w 10.1) (24, 25). In
countries such as Saudi Arabia, Sudan, and Taiwan, with semi-
arid, arid dry, and tropical weather conditions,A. flavus appears to
be the main etiological agent of invasive aspergillosis (26, 27).
In the study samples described here, A. flavus was the second
most common species, responsible for 22% of all clinical isolates.
The prevalence ofA. flavus in our collection is substantially higher
than the rates demonstrated in recentmulticenter studies from the
United States and Spain (9 to 10%) (28, 29). Indeed, this observed
prevalence is also considerably higher than the 10% rates of A.
flavus found in a worldwide collection represented by 771 Asper-
gillus clinical samples obtained from 62 medical centers (30).
In addition to the different species we found within the section
Flavi, we characterized a large spectrum of cryptic species related
to sections Circumdati, Fumigati, Nigri, Usti, and Nidulantes.
Overall, cryptic species of Aspergillus represented 19% of our col-
lection. This number agrees closely with the rate recently found by
FIG 2 Aspergillus section Nigri. Most-parsimonious tree obtained from a heuristic search based on parsimony analysis of the data produced from the BT2 and
CAL genes combined. The numbers at the nodes of the branches are bootstrap values/Bayesian posterior probability. Clinical isolates are highlighted in bold type.
T, type strain; NT, neotype strain. Bar, 0.1 nucleotide changes between taxa.
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Alastruey-Izquierdo et al. (29) by testing 325 isolates in filamen-
tous fungi. The most frequently identified cryptic species being
reported in both Europe and the United States are Aspergillus al-
liaceus (section Flavi), Aspergillus tubingensis (section Nigri),
Aspergillus calidoustus (sectionUsti), andAspergillus lentulus (sec-
tion Fumigati) (28, 29, 31). In Brazil, unlike in Europe and the
United States, A. tamarii and A. awamori were the two cryptic
speciesmost commonly foundwithin the sections Flavi andNigri,
respectively.
Of note, some cryptic species described in our study had never
been reported in human hosts such as A. arachidicola, A. tabaci-
nus, A. tennesseensis, A. creber, and A. transmontanensis. As illus-
trated in Table 2, all of these strains were related to episodes of
colonization and/or infection of the respiratory tract. In addition,
we also found 5 other cryptic species already described in the
literature as agents of human infections (A. ochraceus, A. tamarii,
A. nomius, A. thermomutatus, and A. foetidus [3, 11, 32]).
In terms of antifungal susceptibility, it is notable that almost
90% of all cryptic species exhibited susceptibility to the 3 tria-
zoles tested. The exceptions were strains representative of A.
calidoustus,A. ochraceus, andA. thermomutatus that were less sus-
ceptible in vitro against at least one of the three triazoles tested.
The reduced in vitro susceptibility to triazoles of A. thermomu-
tatus and A. calidoustus has also been demonstrated in other stud-
ies (10, 33).
We conclude that there is a great diversity of species belonging
to theAspergillus genus causing human colonization and/or infec-
tions inBrazil, with a higher occurrence ofAspergillus sectionFlavi
compared to U.S. and European medical centers. We emphasized
the importance of accurate identification and in vitro susceptibil-
FIG 3 Aspergillus sectionNidulantes. Most-parsimonious tree obtained from a heuristic search based on parsimony analysis of the data produced from the BT2
and CAL genes combined. The numbers at the nodes of the branches are bootstrap values/Bayesian posterior probability. Clinical isolates are highlighted in bold
type. T, type strain; NT, neotype strain. Bar, 0.1 nucleotide changes between taxa.
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ity tests of clinical Aspergillus species. This will allow the genera-
tion of consistent data about potential peculiarities of infections
caused by rare and cryptic species with regard to reservoirs, natu-
ral history, and clinical response to antifungal drugs.
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